Our Story

Pluristyx was established in 2018 as an advanced therapy tools company to help companies and researchers solve manufacturing challenges in the field of drug development, regenerative medicine, and cell and gene therapy. Pluristyx provides seamless client support by offering CMC consulting, contract development services, and research- and clinical-grade Ready-To-Differentiate (RTD™) Pluripotent Stem Cells at a commercial scale and under GMP conditions. In doing so, Pluristyx effectively decouples the hassles of expansion and banking from differentiation and product development, allowing early-stage companies to focus precious resources on therapeutic application rather than manufacturing hurdles, with the ultimate goal of advancing promising laboratory discoveries into patients.  

Ben Fryer, PhD

Chief Executive Officer

Jason Carstens, PhD

Chief Operating Officer

Brian Hawkins, PhD

Chief Technology Officer

Kaye Reiter, PhD, JD

General Counsel

Leadership Team

Follow

©2018 by Pluristyx, Inc. All Rights Reserved.